Here’s a bold statement: What if we could personalize breast cancer screening to save lives more effectively while reducing unnecessary procedures? That’s the promise of risk-based screening, and a groundbreaking study just shed new light on its potential—but not everyone is convinced. Let’s dive in.
A recent study published in JAMA on December 12 suggests that risk-based breast cancer screening is both safe and acceptable, though it doesn’t significantly lower biopsy rates. Led by Dr. Laura Esserman of the University of California, San Francisco, the Women Informed to Screen Depending on Measures of Risk (WISDOM) study compared women undergoing risk-based screening with those receiving annual mammograms. The key finding? Women in the risk-based group had rates of stage IIB cancers that were noninferior to those in the annual screening group. But here’s where it gets controversial: despite fewer mammograms in the risk-based group, biopsy rates remained similar between the two groups.
And this is the part most people miss: The study’s approach didn’t just focus on screening—it also stratified individual risk for developing breast cancer, laying the groundwork for more refined screening methods. Proponents argue this could shift resources to high-risk women, optimizing screening frequency, supplemental imaging, and preventive measures. Imagine tailoring screening to each woman’s unique risk profile—sounds revolutionary, right?
The WISDOM trial, still ongoing, involves 28,372 women with an average age of 54. Of these, 77% were non-Hispanic white. Participants were split into two groups: 14,212 in the risk-based screening group and 14,160 in the annual screening group. The risk-based group saw 30 stage IIB cancers per 100,000 person-years, compared to 48 in the annual screening group—a statistically noninferior result. Biopsy rates were nearly identical, with 943 biopsies in the risk-based group and 1,029 in the annual group.
Interestingly, the study found that as risk categories increased, so did the cumulative incidence of cancer, biopsies, mammograms, and MRIs. Here’s the kicker: 89% of participants in the observational cohort chose risk-based screening, suggesting widespread acceptance. The authors emphasize that improved risk models, better communication, and shared decision-making could further enhance this approach. They’re already working on WISDOM 2.0, which will incorporate polygenic risk scores for more precise, ancestry-based assessments.
But not everyone is on board. The American College of Radiology (ACR) responded skeptically, arguing the study’s design and results don’t justify changes to current screening policies. They pointed out issues like low adherence rates, limited accrual, and the trial’s focus on stage IIB cancers—tumors likely already detectable through clinical or self-exams. The ACR also questioned the feasibility of replicating the study’s intensive interventions in real-world settings and criticized the variability of polygenic risk scores. Is the ACR being overly cautious, or do they have a point?
This debate raises a critical question: Can personalized screening truly outperform traditional methods, or are we introducing unnecessary complexity? The study’s authors believe risk-based approaches hold promise, but the ACR’s concerns can’t be ignored. What do you think? Is risk-based screening the future, or should we stick to what we know? Let’s keep the conversation going in the comments—your perspective matters!
